Acyclovir Production Cost Reports

The report provides a detailed analysis essential for establishing an Acyclovir production plant. It encompasses all critical aspects necessary for Acyclovir production, including the cost of Acyclovir production, Acyclovir plant cost, Acyclovir production costs, and the overall Acyclovir production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Acyclovir production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Acyclovir is an antiviral medication primarily utilised to manufacture medicines for treating herpes simplex (HSV), varicella-zoster (chickenpox and shingles), and acute herpetic keratitis. It is formulated into oral tablets, capsules, suspensions, topical creams, ointments, buccal tablets, and ophthalmic ointments to meet different clinical requirements. Applications in HIV management, Eczema herpeticum, cytomegalovirus prophylaxis, and oral hairy leucoplakia are niche but relevant in hospital and speciality pharmaceutical production.

The primary market drivers for acyclovir include the rising global prevalence of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections, which create sustained demand for effective antiviral treatments. The global rise in awareness among healthcare providers and patients about antiviral medication benefits, coupled with growing healthcare expenditure and government initiatives, enhances access to acyclovir treatments. The expanding geriatric population prone to shingles and the shift towards affordable generic formulations further propel market growth. Additionally, advancements in drug formulations, such as topical creams, oral tablets, and sustained-release technologies, improve treatment efficacy and patient compliance, which contributes to the demand.

Factors such as solvent choice during synthesis, favouring non-toxic alternatives over hazardous compounds, affect both product safety and process economics, which impacts industrial acyclovir procurement. Also, process factors like the adoption of hot-melt extrusion and continuous production improve production efficiency, quality, and reproducibility, which further influence the overall procurement.

Raw Material for Acyclovir Production

According to the Acyclovir production plant project report, the various raw materials for Acyclovir production include 5-aminoimidazole-4-carboxamide and 3-oxy-4-chlorobutanol acetate.

Production Process of Acyclovir

The extensive Acyclovir production cost report consists of the following major industrial production process:

1. Production via alkylation: The production process of acyclovir (ACV), starting with 5-aminoimidazole-4-carboxamide, involves several well-defined steps. The process begins with the alkylation of 5-aminoimidazole-4-carboxamide using 3-oxy-4-chlorobutanol acetate to form a substituted intermediate. This is followed by condensation with benzoyl othiocyanate (PhCONCS) via reflux in acetone, producing a key intermediate. The final step involves cyclodesulfurisation and hydrolysis under alkaline aqueous conditions, utilising metal salts such as Cu²?, Ag?, or Hg²? to catalyse cyclisation and sulfur removal for a high yield of acyclovir.

Properties of Acyclovir

Acyclovir is a white to light yellow crystalline powder with the molecular formula C8H11N5O3 and a molar mass of 225.21 g/mol. It has a melting point in the range of 256-257 degree Celsius and a rough estimated boiling point of 366.7 degree Celsius. The density is about 1.3654 g/cm³, and it has a refractive index near 1.8. It is slightly soluble in water (0.7 to 1.3 mg/mL at 25 degree Celisus), very slightly soluble in ethanol, but freely soluble in dimethyl sulfoxide (DMSO). Acyclovir has two dissociation constants (pKa) at approximately 2.27 and 9.25, reflecting acidic and basic functional groups. It is chemically described as an acyclic nucleoside analogue of guanine with antiviral activity primarily against herpes simplex virus types 1 and 2 and varicella-zoster virus.

Physically stable, acyclovir is sensitive to strong oxidising agents but generally stable under standard pharmaceutical storage conditions (2-8 degree Celsius). Its low water solubility contributes to limited oral bioavailability of about 15-20%, often requiring high doses or alternate delivery methods. It has a low logP value (~-0.6), indicating it is hydrophilic with limited membrane permeability, consistent with its classification as a BCS Class III drug (high solubility, low permeability).